Voyager Therapeutics (VYGR) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$27.9 million.
- Voyager Therapeutics' Income towards Parent Company fell 20840.34% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 58988.41%. This contributed to the annual value of -$65.0 million for FY2024, which is 14912.11% down from last year.
- As of Q3 2025, Voyager Therapeutics' Income towards Parent Company stood at -$27.9 million, which was down 20840.34% from -$33.4 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Income towards Parent Company registered a high of $124.0 million during Q1 2023, and its lowest value of -$34.5 million during Q4 2024.
- Its 5-year average for Income towards Parent Company is -$7.7 million, with a median of -$22.2 million in 2023.
- As far as peak fluctuations go, Voyager Therapeutics' Income towards Parent Company tumbled by 56669.3% in 2022, and later surged by 68184.72% in 2023.
- Quarter analysis of 5 years shows Voyager Therapeutics' Income towards Parent Company stood at $5.1 million in 2021, then crashed by 566.69% to -$23.6 million in 2022, then surged by 338.86% to $56.4 million in 2023, then tumbled by 161.15% to -$34.5 million in 2024, then grew by 19.12% to -$27.9 million in 2025.
- Its Income towards Parent Company was -$27.9 million in Q3 2025, compared to -$33.4 million in Q2 2025 and -$31.0 million in Q1 2025.